|  |
| --- |
| IRB #: |
| Principal Investigator: |
| Study Title:  |
| Name of Sponsor/Funding Agency:  | [ ]  Not Applicable |
| Name of the party to whom this financial disclosure applies: |
| Position of the party to whom this financial disclosure applies: [ ]  Principal Investigator (“PI”) [ ]  Sub-Investigator (“Sub-I”) [ ]  Research Staff [ ]  Spouse or dependent child of PI or Sub-I |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Check the appropriate box(es) below:**

|  |  |
| --- | --- |
| [ ]  | I, nor any member of my immediate family, do **NOT** have a **Financial Interest or Relationship to Disclose** *[Please note: If this box is checked, no further items are required, you may proceed to the signature]* |
| [ ]  | I and/or a member of my immediate family, have a **Financial Interest or Relationship to Disclose** with the above-referenced sponsor and/or study *[Check all interests that apply below]* |

 |
| Mark “**Yes**” or “**No**” to indicate whether the financial interests/arrangements described apply to the party listed above. For each item answered “**Yes**,” provide additional information in the box on page 2. If any information provided here changes during the course of the study, or within one year after the last participant completes the study as specified in the protocol, notify TCH IRB immediately. |
| 1. | An executive, director, or employee of the sponsor of this study. | [ ]  Yes [ ]  No |
| 2. | An ownership interest, stock options or other financial interest in this study that is valued at $5,000 or more\* or 5 % or greater\* ownership. | [ ]  Yes [ ]  No |
| 3. | For publicly traded entities: the value of any remuneration received from the entity in the past 12 months plus the current value of any equity interest in the entity exceeds $5,000\*, and this financial interest reasonably appears to be related to the investigator’s responsibilities for this study. For purposes of this definition, “remuneration” includes salary and any other payment for services not otherwise identified as salary (e.g., consulting fees, honoraria, paid authorship) and “equity interest” includes any stock, stock option, or other ownership interest as determined through reference to public prices or other measures of fair market value. | [ ]  Yes [ ]  No |
| 4. | For non-publicly traded entities: the aggregate value of any remuneration received from the entity in the past 12 months exceeds $5,000\* or any equity interest is held (e.g., stock, stock option, or other ownership interest) and this financial interest reasonably appears to be related to the investigator’s responsibilities for this study. | [ ]  Yes [ ]  No |
| 5. | Intellectual property or other proprietary rights and interest (e.g. patents, copyrights, trademarks, licensing agreements) that reasonably appear to be related to the investigator’s responsibilities for this study (e.g. rights/interest in the tested product); includes receipt of income related to such rights and interests. | [ ]  Yes [ ]  No |
| 6. | Any significant equity interest in this study’s sponsor (i.e., any ownership interest, stock options, or other financial interest) whose value cannot be readily determined through reference to public prices. This generally applies to interests in a sponsor that is not a publicly-traded entity. | [ ]  Yes [ ]  No |
| 7. | Reimbursed or sponsored travel (i.e., that which is paid on behalf of the investigator and not reimbursed to the investigator so that the exact monetary value may not be readily available) related to the investigator’s responsibilities for this study; provided, however, that this disclosure does not apply to travel that is reimbursed or sponsored by a Federal, state, or local government agency, an institution of higher education as defined at 20 U.S.C.1001(a), an academic teaching hospital, or a research institute that is affiliated with an institution of higher education. | [ ]  Yes [ ]  No |
| 8. | Financial arrangement entered into between the sponsor of this study and the investigator whereby the value of the compensation for conducting the study could be influenced by its outcome. For example, compensation that is explicitly greater for a favorable outcome, or compensation to the investigator in the form of an equity interest in the sponsor or in the form of compensation tied to the sales of the product, such as royalty interest | [ ]  Yes [ ]  No |

\**This threshold limit applies to the aggregated financial interests of the PI or Sub-I including immediate family defined as spouse, dependents or members of his/her household.*

For each item marked “Yes,” describe the conflict (including its size and nature) and explain your plan to manage the conflict and minimize its impact on the conduct of this study***. If multiple items were marked “Yes,” reference the item number and provide a separate explanation as to each:***

|  |
| --- |
|  |

|  |
| --- |
| **I, the submitting party, attest that the information provided above is true and accurate and is submitted by, or under the authority of the Principal Investigator.** **Print Name Signature****Phone Number E-mail Address Date** |